West Pharmaceutical Services is laying off 100 staff as part of restructuring efforts after its third quarter results fell short of expectations, despite operating profit increasing by 45 per cent.
Increased focus on international markets, soaring demand for finished dosage forms and improved capacity usage helped India-based CMO Granules posting record revenues.
We look ahead to CPhI 2009 which takes place in Madrid, Spain next week and will showcase the world’s leading ingredients, contract services, machinery and biotech companies.
US firm 3M Drug Delivery Systems has set its sights on the Asia-Pacific region, with a new lab in Singapore which, it says, will help it better serve both local and international markets.
Dutch contract delivery services firm OctoPlus says it will cut 35 jobs as part of ongoing efforts to boost efficiency, improve competitiveness and broaden its client base and revenue streams.
Fierce competition from India and China means it is unlikely that CROs and CMOs in CEE can generate sustainable growth, according to a report that believes the service model must be a “stepping stone” to creating innovative R&D businesses.
Having filed for bankruptcy in December Introgen Therapeutics has sold its assets, including management and technical team, to Vivante, a company that formed last week as a contract manufacturing organisation (CMO).
Dalton Pharma Services has rolled out a new formulation development service that completes the firm’s contract drug manufacturing offering according to CEO Peter Pekos.
A totally outsourced model of discovery is “probably valid”, according to a report that believes pharma must overhaul its operations because its business model is in danger of becoming “irrelevant”.
Patheon has posted “disappointing” Q3 results, with manufacturing difficulties in Puerto Rico, a slowdown in demand for development services and reduced client demand for some products impacting on revenues.
Dishman is pushing ahead with its international expansion, increasing efforts to win contracts in the US and Japan and nearing completion of a facility Shanghai, China, which is the first it has built outside of India.
Biotechs that partner or outsource in emerging markets are better equipped to innovate and prosper, according to research that warns “if you are not in Shanghai, Mumbai, or Dubai, watch out".
With Lonza and JLL competing over Patheon Outsourcing-Pharma looks at what the CMO offers to a prospective buyer, analysing its global manufacturing capacity and backlog using interactive maps and graphs.
Bangladesh represents a “huge opportunity” to pharma, according to the CEO of Amreteck Pharma who believes that CMOs will be attracted by the low costs, which undercut China, and help the industry grow to $10bn (€6.9m) in 10 years.
CMO Avid Bioservices’ revenues rose by 74 per cent to $2.1m (€1.5m) in Q2, generating a further $7m from its parent company, and it has plans to boost output and become a leader in mammalian cell culture production.
The Californian budget deficit presents a “real risk to future biotech investments”, according to the CEO of BayBio who explained to how the industry now has a difficult relationship with the state.
Sweden’s XSpray Microparticles says its new particle plant proves its RightSize tech can be scaled-up for industrial applications and will be a boost for its contract services offering.
Chemicals firm Durect will supply drugmaker King Pharmaceuticals with two excipients used in the manufacture of the candidate anti-abuse painkiller Remoxy in an agreement signed last week.
Ark Therapeutics is using its expertise and spare capacity to move into the contract manufacturing sector and is hoping to sign deals to produce the DNA-based medicine.
Canadian contractor Patheon has welcomed the $460m (€321m) takeover offer from Switzerland's Lonza that could, according to some observers, spark a bidding war with rival suitor, US group JLL Patheon Holdings.
The EMEA has approved Patheon’s facility in Manati, Puerto Rico, allowing the CMO to import to Europe and improving its fortunes on the island that caused it financial problems in the past.
Wuxi PharmaTech’s China-based laboratory services grew by 23 per cent in Q2, outstripping expectations and resulting in the company revising its guidance for the business segment.
India’s outsourcing sector is growing at 43 per cent, according to a new report that predicts the country will take a bigger share of the global market as concerns about operating there diminish.
Meridian Life Science (MLS) has completed the expansion of its cGMP biotech facility, which will enable the contract production of vaccines and viral based products for Phase I trials.
US contract manufacturer West Pharmaceutical Services has purchased French device firm Plastef Investissements’ drug delivery business, adding the eris safety syringe system to its offering.
India and China share many similarities as outsourcing locations but there are also significant differences that are important to understand before making a commitment, according to a report.
Novasep has bolstered its upstream processing capabilities by acquiring Henogen, a Belgium-based CMO that has biotech development and cGMP manufacturing expertise.
Demand for biopharmaceutical contract manufacturing will grow 16 per cent a year over the next five years, according to analysis by US market research group HighTech Business Decisions.
3M’s drug delivery unit believes its new plasma coating and face seal valve pMDI technologies help protect APIs and will mean that more drugs can be delivered via inhalation.
3M Drug Delivery Technologies has expanded its respiratory drug delivery system offering with its Taper DPI which, it claims, makes carrier compounds unnecessary and will help drug formulators save millions.
Power outages cost India $9.2bn (€6.5bn) in 2008, according to a report, with the disruptions causing direct losses in numerous sectors, including pharma and biotech.
Portuguese contract manufacturing organisation (CMO) Hovione plans to invest €2m ($3m) in a new R&D unit in the capital Lisbon, as expansion space at its active pharmaceutical ingredient (API) plant in Loures is limited.
Canada’s Patheon has been contracted to commercialise treatments for allergy and depression using the Oros controlled release technology at its manufacturing facility in Cincinnati, US.
Patheon chief Wes Wheeler says the drop in Q1 losses the firm recently reported is due to the “restructuring activities and rigorous cost containment efforts” it enacted towards the end of last year.
It is not compulsory to respond to form 483s detailing deficiencies at a facility but the FDAs latest guidance fully recommends companies do so to avoid being issued with a warning letter.
Almac Sciences, part of global contracting group Almac, chose this year’s Informex in San Francisco, US to showcase its solid state chemistry (SSC) services to drugmakers in North America.
Since its inauguration last year, IPEC China has been working to improve the quality of excipient manufacturing in the country. in-PharmaTechnologist spoke with organisation president Nevin Cheng about the steps the body has taken so far and what it will...
Blue Reference has formed a Quality by Design Product Development Consortium (QbD PDC) to provide a forum for the improvement of its process analytics software.
DPT Laboratories chose this year’s AAPS in Atlanta to showcase its research and development capability with a unique poster presentation examining the role of various excipients in nasal drug delivery applications.
Patheon has signed a slew of agreements to boost its portfolio of contract drug development and manufacturing services, forging new alliances with Omnicare, Depomed, Senopsys and Solvias.
Jubilant Organosys, India's largest custom research and manufacturing services (CRAMS) provider, has reorganised its business in North America in the wake of its recent acquisitions of HollisterStier Laboratories and Draxis Specialty Pharmaceuticals.
Covance has defied challenging market conditions and posted positive results for the third quarter, with the company believing more major R&D outsourcing contracts are a possibility.
The pharmaceutical industry must adapt its processes and strategies to cope with a new, tougher operating environment, according to Stefan Borgas, CEO of Lonza.
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...
